CARMEL, Ind., Jan. 18, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, today announced a one-year, $480,000 contract from the Indiana Department of Health (IDOH) to administer public health and healthcare readiness assessments.
Under the agreement, Syra Health's public health experts will be evaluating how existing hazards and risks impact public health, public health infrastructure, and behavioral health within the state of Indiana.
"These are important assessments because they allow us to identify where any gaps may be and how they can be urgently addressed, said Srikant Devaraj, PhD, Vice President of Health Analytics, Syra Health.
Part of the agreement also includes identifying the greatest risks to public health and the healthcare system of Indiana, as well as identifying where IDOH and its local partners should focus their resources to create a healthcare network for all Indiana residents.
"As states wrestle with ongoing threats to public health such as mental and behavioral health, we anticipate additional calls for similar work," said Dr. Deepika Vuppalanchi, CEO, Syra Health.
The Syra Health contract with the Indiana Department of Health includes the potential for a one-year contract extension.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors outlined in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications & Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.
Last Trade: | US$0.94 |
Daily Change: | -0.06 -5.86 |
Daily Volume: | 138,116 |
Market Cap: | US$6.220M |
August 08, 2024 July 30, 2024 May 14, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB